BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Carb-X - ECPv6.15.18//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Carb-X
X-ORIGINAL-URL:https://carb-x.org
X-WR-CALDESC:Events for Carb-X
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Europe/London
BEGIN:DAYLIGHT
TZOFFSETFROM:+0000
TZOFFSETTO:+0100
TZNAME:BST
DTSTART:20170326T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0100
TZOFFSETTO:+0000
TZNAME:GMT
DTSTART:20171029T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0000
TZOFFSETTO:+0100
TZNAME:BST
DTSTART:20180325T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0100
TZOFFSETTO:+0000
TZNAME:GMT
DTSTART:20181028T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0000
TZOFFSETTO:+0100
TZNAME:BST
DTSTART:20190331T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0100
TZOFFSETTO:+0000
TZNAME:GMT
DTSTART:20191027T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0000
TZOFFSETTO:+0100
TZNAME:BST
DTSTART:20200329T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0100
TZOFFSETTO:+0000
TZNAME:GMT
DTSTART:20201025T010000
END:STANDARD
END:VTIMEZONE
BEGIN:VTIMEZONE
TZID:Europe/Berlin
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20170326T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20171029T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20180325T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20181028T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20190331T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20191027T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20200329T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20201025T010000
END:STANDARD
END:VTIMEZONE
BEGIN:VTIMEZONE
TZID:Asia/Kolkata
BEGIN:STANDARD
TZOFFSETFROM:+0530
TZOFFSETTO:+0530
TZNAME:IST
DTSTART:20180101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VTIMEZONE
TZID:Europe/Paris
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20180325T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20181028T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20190331T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20191027T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20200329T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20201025T010000
END:STANDARD
END:VTIMEZONE
BEGIN:VTIMEZONE
TZID:America/New_York
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20170312T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20171105T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20180311T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20181104T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20190310T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20191103T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20200308T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20201101T060000
END:STANDARD
END:VTIMEZONE
BEGIN:VTIMEZONE
TZID:Africa/Accra
BEGIN:STANDARD
TZOFFSETFROM:+0000
TZOFFSETTO:+0000
TZNAME:GMT
DTSTART:20170101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VTIMEZONE
TZID:UTC
BEGIN:STANDARD
TZOFFSETFROM:+0000
TZOFFSETTO:+0000
TZNAME:UTC
DTSTART:20170101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;VALUE=DATE:20190321
DTEND;VALUE=DATE:20190323
DTSTAMP:20260404T145934
CREATED:20190201T193139Z
LAST-MODIFIED:20190220T163600Z
UID:2260-1553126400-1553299199@carb-x.org
SUMMARY:BSAC Spring Conference 2019
DESCRIPTION:Global views\, local problems: Innovative solutions to AMR and infection challenges. \nThe British Society for Antimicrobial Chemotherapy (BSAC) 2019 Spring Conference offers a state of the art overview of the infection management and antimicrobial resistance landscape. The programme includes keynote lectures\, plenary and parallel sessions\, debates and an opening series of spotlight presentations – offering insights into the latest in drug discovery and development\, socio-economic challenges\, new and emerging treatments and diagnostics and debates and challenges policies and usage of antibiotic regimens.  Globally focused and locally relevant\, the conference brings together key opinion leaders\, researchers and clinicians from across Europe and further afield. Alongside the networking and exhibition areas\, this event offers outstanding opportunities for education and engagement to all delegates.
URL:https://carb-x.org/event/bsac-spring-conference-2019/
LOCATION:International Convention Center\, 8 Centenary Square\, Birmingham\, B1 2EA\, United Kingdom
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20190314
DTEND;VALUE=DATE:20190316
DTSTAMP:20260404T145934
CREATED:20190201T192824Z
LAST-MODIFIED:20190214T181713Z
UID:2256-1552521600-1552694399@carb-x.org
SUMMARY:The 12th Berlin Conference on Life Sciences - Novel Antimicrobials and AMR Diagnostics 2019
DESCRIPTION:Speakers include Kevin Outterson\, CARB-X Executive Director. \nThe Novel Antimicrobials and AMR Diagnostics 2019 conference is a platform for SMEs\, start-ups\, big pharma\, academia\, investors and public institutions to discuss strategies and the specific challenges faced by SMEs in bringing new antimicrobial treatments and diagnostics to the market. \n 
URL:https://carb-x.org/event/thje-12th-berlin-conference-on-life-sciences-novel-antimicrobials-and-amr-diagnostics-2019/
LOCATION:Radisson Blu Hotel\, Karl-Liebknecht-Strasse 3\, Berlin\, 10178\, Germany
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20190306
DTEND;VALUE=DATE:20190307
DTSTAMP:20260404T145934
CREATED:20190206T154939Z
LAST-MODIFIED:20190206T154939Z
UID:2336-1551830400-1551916799@carb-x.org
SUMMARY:US FDA Regulatory Approval Process for Anti-microbials Workshhop
DESCRIPTION:Workshop hosted by the Centre for Cellular And Molecular Platforms (C-CAMP)\, a member of the CARB-X Accelerator Network.
URL:https://carb-x.org/event/us-fda-regulatory-approval-process-for-anti-microbials-workshhop/
LOCATION:C-CAMP\, Chausa\, Bengaluru\, India
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Paris:20190221T170000
DTEND;TZID=Europe/Paris:20190221T183000
DTSTAMP:20260404T145934
CREATED:20190206T170743Z
LAST-MODIFIED:20190214T192431Z
UID:2345-1550768400-1550773800@carb-x.org
SUMMARY:Webinar - NIAID Resources to Facilitate Discovery & Development of Anti-Infectives
DESCRIPTION:Speakers include Ann Eakin\, Senior Scientific Officer Office of Biodefense\, Research Resources & Translational Research\, DMID/NIAID/NIH\, member of the CARB-X Joint Oversight Committee. \nIn this presentation\, Ann Eakin (US National Institute of Allergy and Infectious Diseases\, NIAID) will provide an overview of the various mechanisms of support offered by NIAID to facilitate the discovery and development of drugs\, vaccines and diagnostics targeting infectious diseases. The types of support that will be discussed are grants and contracts\, as well as preclinical and clinical research services that aim to reduce risk and advance product development efforts. Researchers from any country and from any type of institution (academia\, industry\, non-profit) are eligible to apply for nearly all types of support mechanisms offered by NIAID\, irrespective of prior or current NIH funding. \nAnn’s presentation will be complemented by a short presentation of Dan Pevear\, Founder and Senior Vice President\, Biology and Grants Development\, VenatoRx Pharmaceuticals\, in which he will share VenatoRx’ experience with NIAID support mechanisms. \nThe presentations will be followed by a Q&A session. \n 
URL:https://carb-x.org/event/webinar-niaid-resources-to-facilitate-discovery-development-of-anti-infectives/
LOCATION:Webinar\, 765 Commonwealth Avenue\, Boston\, MA\, 02215\, United States
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20190204
DTEND;VALUE=DATE:20190206
DTSTAMP:20260404T145934
CREATED:20190201T192309Z
LAST-MODIFIED:20190201T192309Z
UID:2253-1549238400-1549411199@carb-x.org
SUMMARY:Hamied Foundation UK-India Antimicrobial Resistance Meeting 2019
DESCRIPTION:The meeting is being organised as part of a programme of work to strengthen the research links between the UK and India with the specific aim of jointly addressing the challenge of AMR. \n 
URL:https://carb-x.org/event/hamied-foundation-uk-india-antimicrobial-resistance-meeting-2019/
LOCATION:The Hallam Conference Centre\, 44 Hallam Street\, London\, United Kingdom
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20190129T110000
DTEND;TZID=America/New_York:20190129T123000
DTSTAMP:20260404T145934
CREATED:20181210T194947Z
LAST-MODIFIED:20190124T152941Z
UID:2050-1548759600-1548765000@carb-x.org
SUMMARY:REVIVE Webinar: Clinical development for non-developers Part 3: Antibacterial Drug Enhancer Combinations and Non-traditional Products
DESCRIPTION:On the 29th of January 2019\, Ian Friedland\, Sumathi Nambiar\, Mair Powell\, and David Shlaes will join us for a live webinar about antibacterial drug enhancer combinations and non-traditional products. Following their short presentations\, the speakers will be available on the line to respond to your questions.
URL:https://carb-x.org/event/revive-webinar-clinical-development-for-non-developers-part-3-antibacterial-drug-enhancer-combinations-and-non-traditional-products/
LOCATION:WEBINAR\, Webinar\, Webinar\, United States
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20190117
DTEND;VALUE=DATE:20190118
DTSTAMP:20260404T145934
CREATED:20181101T161314Z
LAST-MODIFIED:20181101T161534Z
UID:1981-1547683200-1547769599@carb-x.org
SUMMARY:ECRAID-Plan Kick-off meeting
DESCRIPTION:The European Clinical Research Alliance on Infectious Diseases (ECRAID) focuses on two major challenges: emerging infectious diseases (EID) with epidemic or pandemic potential\, caused by new or re-emerging pathogens\, and antimicrobial resistance (AMR). This meeting aims to bring together the ECRAID-Plan Project Consortium\, Working Group\, and key stakeholders to constructively discuss ECRAID and its sustainable solutions to protect Europe\, and beyond\, from AMR and EID threats over the long-term.  This is a closed meeting. \nKevin Outterson\, Executive Director of CARB-X\, will be on the stakeholder advisory panel.  Keynote speakers include EU Commissioner for Research\, Science and Innovation\, Carlos Moedas\, and Wellcome Trust Director\, Jeremy Farrar. \n 
URL:https://carb-x.org/event/ecraid-plan-kick-off-meeting/
LOCATION:Brussels\, Belgium\, Brussels\, Belgium
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20190115T120000
DTEND;TZID=America/New_York:20190115T130000
DTSTAMP:20260404T145934
CREATED:20181030T183248Z
LAST-MODIFIED:20190108T215134Z
UID:1974-1547553600-1547557200@carb-x.org
SUMMARY:CARB-X: Combating Antibiotic Resistance Globally
DESCRIPTION:With Kevin Outterson.  A Boston University Alumni Association special webinar event for BU alumni\, but all are welcome to join. Register online
URL:https://carb-x.org/event/webinar-combating-antibiotic-resistance-globally/
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20181207T083000
DTEND;TZID=America/New_York:20181207T190000
DTSTAMP:20260404T145934
CREATED:20181119T174550Z
LAST-MODIFIED:20181119T174550Z
UID:2018-1544171400-1544209200@carb-x.org
SUMMARY:6th annual meeting of the Boston Area Antibiotic Resistance Network
DESCRIPTION:Speakers include Karen Gallant\, Global Program Director of CARB-X.
URL:https://carb-x.org/event/6th-annual-meeting-of-the-boston-area-antibiotic-resistance-network/
LOCATION:Starr Center for Conferences\, 185 Cambridge St.\, Boston\, MA\, 02114\, United States
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20181120T073000
DTEND;TZID=America/New_York:20181120T084500
DTSTAMP:20260404T145934
CREATED:20181015T185245Z
LAST-MODIFIED:20181015T185245Z
UID:1907-1542699000-1542703500@carb-x.org
SUMMARY:Call to Action Side Event: Access and stewardship plans during antibiotic research and development
DESCRIPTION:This event is an invitation-only side event to the 2nd Call to Action on Antimicrobial Resistance hosted by the Access to Medicine Foundation\, the Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator (CARB-X) and the Global Antibiotic Research & Development Partnership (GARDP).  In this session\, the Access to Medicine Foundation\, CARB-X and GARDP will share how they guide\, support and partner with pharmaceutical companies to achieve access and stewardship goals. Presentations will be followed by an open discussion related to the role of different sectors in improving access and stewardship strategies during the R&D process.
URL:https://carb-x.org/event/call-to-action-side-event-access-and-stewardship-plans-during-antibiotic-research-and-development/
LOCATION:Accra\, Ghana\, Accra\, Ghana
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Africa/Accra:20181119T080000
DTEND;TZID=Africa/Accra:20181120T170000
DTSTAMP:20260404T145934
CREATED:20180725T191843Z
LAST-MODIFIED:20180810T185454Z
UID:1662-1542614400-1542733200@carb-x.org
SUMMARY:Call to Action on Antimicrobial Resistance
DESCRIPTION:Wellcome Trust is to co-host a second global conference  to help drive pioneering action to stop the rise and spread of superbugs.  The two-day Call to Action\, taking place in Accra this November\, is co-hosted with the governments of Ghana and Thailand\, and the United Nations Foundation\, and is organized in partnership with the Inter-Agency Coordination Group (IACG) on Antimicrobial Resistance. \nHealth representatives from national governments and agencies\, civil society\, the private sector and global philanthropies will be invited to come together at the Call to Action to focus on how to address the most critical gaps in tackling the development and spread of drug-resistant infections. \nInvitation Only \nAttendees include Kevin Outterson\, Executive Director of CARB-X.
URL:https://carb-x.org/event/call-to-action-on-antimicrobial-resistance/
LOCATION:Accra\, Ghana\, Accra\, Ghana
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20181116
DTEND;VALUE=DATE:20181117
DTSTAMP:20260404T145934
CREATED:20180810T194133Z
LAST-MODIFIED:20180810T194133Z
UID:1722-1542326400-1542412799@carb-x.org
SUMMARY:Max Planck Institute for Innovation and Competition Conference
DESCRIPTION:Additional details to follow. \n  \nPresentation by Kevin Outterson\, Executive Director of CARB-X.
URL:https://carb-x.org/event/max-planck-institute-for-innovation-and-competition-conference/
LOCATION:Berlin\, Berlin\, Germany
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Berlin:20181113T170000
DTEND;TZID=Europe/Berlin:20181113T170000
DTSTAMP:20260404T145934
CREATED:20181030T182904Z
LAST-MODIFIED:20181030T182904Z
UID:1972-1542128400-1542128400@carb-x.org
SUMMARY:GARDP Webinar: Making Safety a Part of Drug Design
DESCRIPTION:This webinar aims at making a presentation of a recent GARDP co-organized conference session accessible to anyone who didn’t have the chance to attend the meeting. \nAfter the showing of the recording of her presentation “Making Safety a Part of Drug Design”\, Claire Sadler will join us online for a live Q&A session. This presentation was part of the GARDP and CARB-X co-organized “Antibiotic Bootcamp for Developers: Preclinical Toxicology” at the ESCMID/ASM Conference on Drug Development to Meet the Challenge of Antimicrobial Resistance in Lisbon in September 2018.  \nSpeaker: Claire Sadler\nModerator: Ursula Theuretzbacher\nHost: François Franceschi \nPlease click here to register.
URL:https://carb-x.org/event/gardp-webinar-making-safety-a-part-of-drug-design/
LOCATION:Webinar
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/London:20181113T150000
DTEND;TZID=Europe/London:20181113T170000
DTSTAMP:20260404T145934
CREATED:20181004T141656Z
LAST-MODIFIED:20181004T141744Z
UID:1846-1542121200-1542128400@carb-x.org
SUMMARY:All-Party Parliamentary Group on Antibiotics: How close are we to meeting the urgent need for new antibiotics?
DESCRIPTION:The All-Party Parliamentary Group on Antibiotics APPG-A exists to raise the profile of antibiotic resistance\, the need to preserve antibiotics through education on their appropriate use including non‐human uses\, the lack of new treatments for bacterial infections and to help accelerate efforts to discover\, research and develop new treatments. \nThe British Society for Antimicrobial Chemotherapy serves as Secretariat to the APPG-A. \nThis meeting will focus on the work of partnership bodies like CARB-X and the Global Antibiotic Research & Development Partnership (GARDP) in relation to antibiotic development\, pipeline coordination\, and the legacy of the DRIVE-AB initiative. \nSpeakers include Kevin Outterson\, Executive Director of CARB-X
URL:https://carb-x.org/event/all-party-parliamentary-group-on-antibiotics-how-close-are-we-to-meeting-the-urgent-need-for-new-antibiotics/
LOCATION:1 Parliament Street\, 1 Parliament Street\, London\, A3212\,\, United Kingdom
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/London:20181112T003000
DTEND;TZID=Europe/London:20181112T133000
DTSTAMP:20260404T145934
CREATED:20181030T184427Z
LAST-MODIFIED:20181030T184427Z
UID:1978-1541982600-1542029400@carb-x.org
SUMMARY:Lecture by Kevin Outterson: Why is a lawyer leading antibiotic R&D at CARB-X?
DESCRIPTION:Kevin Outterson is the N Neal Pike Professor of Health and Disability Law at Boston University and the Executive Director of CARB-X\, the world’s largest product development partnership addressing drug-resistant bacterial infections. He will share his personal stories of how experiences\, skills\, passion and faith converge in the efforts to protect us all from drug-resistant bacterial infections.
URL:https://carb-x.org/event/lecture-by-kevin-outterson-why-is-a-lawyer-leading-antibiotic-rd-at-carb-x/
LOCATION:Wellcome Trust\, Euston Road\, London\, NW1\, United Kingdom
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/London:20181108T080000
DTEND;TZID=Europe/London:20181108T170000
DTSTAMP:20260404T145934
CREATED:20180920T145507Z
LAST-MODIFIED:20180920T145507Z
UID:1826-1541664000-1541696400@carb-x.org
SUMMARY:2018 BioInfect Conference
DESCRIPTION:Antimicrobial resistance is an increasingly serious threat to global public health that requires action across all government sectors and society. BioInfect will look at the critical issues relating to the development of new anti-infectives and the endemic problem of resistance. \n  \nDr. Richard Lawson\, CARB-X Senior Project Manager\, will be delivering the keynote address.
URL:https://carb-x.org/event/2018-bioinfect-conference/
LOCATION:Alderley Park Conference Centre\, Alderly Park\, Cheshire\, SK10 4TG\, United Kingdom
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20181029
DTEND;VALUE=DATE:20181031
DTSTAMP:20260404T145934
CREATED:20180810T193508Z
LAST-MODIFIED:20220803T214004Z
UID:1720-1540771200-1540943999@carb-x.org
SUMMARY:BARDA Industry Day
DESCRIPTION:The Biomedical Advanced Research and Development Authority (BARDA)\, a component of the U.S. Department of Health and Human Services Administration for Strategic Preparedness and Response (ASPR)\, invites you to participate in our annual conference at which you can learn about U.S. Government medical countermeasure priorities\, interact with BARDA and ASPR staff\, and network with public and private sector colleagues working in this space. \nThis year’s theme focuses on the importance of innovation and collaboration.
URL:https://carb-x.org/event/barda-industry-day/
LOCATION:Grand Hyatt Washington\, 1000 H St NW\, Washington\, DC\, 20001\, United States
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20181025
DTEND;VALUE=DATE:20181027
DTSTAMP:20260404T145934
CREATED:20180810T190358Z
LAST-MODIFIED:20180810T190358Z
UID:1704-1540425600-1540598399@carb-x.org
SUMMARY:World Anti-Microbial Resistance Congress 2018
DESCRIPTION:At the 4th Annual World Anti-Microbial Resistance Congress\, over 400 stakeholders will gather in Washington D.C. to discuss critical challenges and opportunities to advance antibiotic and diagnostics development\, improve antimicrobial stewardship practice and incentivize funding and partnering to bring innovation to patients and the healthcare system in need.  Discussions will be addressing 4 key areas: Antibiotic R&D\, Diagnostics\, Antimicrobial Stewardship\, and Innovation Showcase. \nPresentations by Tyler Merkeley of BARDA and Dr. Barry Eisenstein\, Chair of the CARB-X Advisory Board.
URL:https://carb-x.org/event/world-anti-microbial-resistance-congress-2018/
LOCATION:Rits Carlton\, 1150 22nd St NW\, Washington\, DC\, 20037\, United States
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20181023T143000
DTEND;TZID=America/New_York:20181023T173000
DTSTAMP:20260404T145934
CREATED:20180615T173216Z
LAST-MODIFIED:20180709T151020Z
UID:1577-1540305000-1540315800@carb-x.org
SUMMARY:Fostering Investment in the Development of New Antibacterial Treatments - UNCTAD World Investment Forum
DESCRIPTION:Antimicrobial resistant infections (AMR) are on the rise and pose a significant global risk. Developing countries\, in particular\, are vulnerable because they often lack key medical resources. The development of new antibacterial treatments is costly while the return on investment is low. Organized in cooperation with the World Health Organization (WHO)\, the conference will explore solutions to this dilemma\, seeking to facilitate cooperation between biotech firms\, potential investors and governments for AMR investment.
URL:https://carb-x.org/event/fostering-investment-in-the-development-of-new-antibacterial-treatments/
LOCATION:Palais des Nations in Geneva\, 1211\, Geneva\, Switzerland
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20181015
DTEND;VALUE=DATE:20181019
DTSTAMP:20260404T145934
CREATED:20180709T142552Z
LAST-MODIFIED:20180810T185309Z
UID:1625-1539561600-1539907199@carb-x.org
SUMMARY:Grand Challenges Annual Meeting 2018
DESCRIPTION:The Grand Challenges Annual Meeting aims to accelerate the translation of innovation to impact to address the world’s most urgent global health and development problems. The meeting is a forum for researchers to share their work\, learn about cutting-edge advances in the field and build collaborations with other investigators and organizations.  This year the meeting will partially overlap with the 10th World Health Summit. \nHosted by the German Federal Ministry of Education & Research\, Bill & Melinda Gates Foundation\, Grand Challenges Canada\, United States Agency for International Development\, and Wellcome. \nInvitation Only
URL:https://carb-x.org/event/grand-challenges-annual-meeting-2018/
LOCATION:Estrel Hotel\, Sonnenallee 225\, 12057 Berlin\, Germany
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20180926
DTEND;VALUE=DATE:20180928
DTSTAMP:20260404T145934
CREATED:20180810T191613Z
LAST-MODIFIED:20180810T191613Z
UID:1709-1537920000-1538092799@carb-x.org
SUMMARY:Antibacterial Discovery and Development Summit
DESCRIPTION:Helping Antibacterial Development to Move Forward – New discovery platforms\, novel screens and approaches are vital for the discovery of new antibacterials and for ceasing the dangerous trend of multidrug microbial resistance. Cambridge Healthtech Institute’s 5th Annual Antibacterial Discovery and Development track will focus on the general\, strategic issues and solutions that would allow new antibacterial development to move forward. The conference will be held as part of the 5th Annual Re-Entering Antibacterial Discovery and Development Summit\, and it will be followed by Targeting Gram-Negative Pathogens. \nKevin Outterson\, Executive Director of CARB-X to speak about funding opportunities with CARB-X on September 27th at 8:25am and join the panel discussion at 10:20am. \nMark Albrecht of BARDA to speak on how BARDA is addressing the global threat of antimicrobial resistance on September 27th at 8:45am. \n 
URL:https://carb-x.org/event/antibacterial-discovery-and-development-summit/
LOCATION:Sheraton Boston\, 39 Dalton Street\, Boston\, MA\, 02199\, United States
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20180925T180000
DTEND;TZID=America/New_York:20180925T210000
DTSTAMP:20260404T145934
CREATED:20180810T192224Z
LAST-MODIFIED:20180919T171915Z
UID:1713-1537898400-1537909200@carb-x.org
SUMMARY:The AMR Challenge Launch Event
DESCRIPTION:The AMR Challenge encourages global leaders to make formal commitments that further progress against antimicrobial resistance. Your efforts could contribute to solutions that protect humans\, animals\, and the environment from this global threat. \nThe first batch of commitments will be unveiled at a United Nations (UN) General Assembly side event on September 25\, and will commence a “commitment year” that invites organizations worldwide to participate. \nAttendees include Alison Haight\, CARB-X Director of Finance
URL:https://carb-x.org/event/the-amr-challenge/
LOCATION:The Roosevelt Hotel\, 45 E 45th St\, New York City\, NY\, 10017\, United States
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20180914T100000
DTEND;TZID=America/New_York:20180914T113000
DTSTAMP:20260404T145934
CREATED:20180907T202401Z
LAST-MODIFIED:20180907T202401Z
UID:1785-1536919200-1536924600@carb-x.org
SUMMARY:FDA Commissioner Unveils Plan to Combat Antibiotic Resistance - Live Webcast
DESCRIPTION:At least 2 million Americans a year contract an antibiotic-resistant infection\, the Centers for Disease Control and Prevention reports. So\, what can the U.S. do to safeguard public health amid the growing threat of these superbugs? \nTune in to a live webcast as Dr. Scott Gottlieb\, commissioner of the U.S. Food and Drug Administration\, announces the agency’s plans to combat antibiotic resistance. \nFollowing Gottlieb’s remarks\, a panel of FDA senior officials will discuss aspects of the plan in more detail and take questions from the audience.
URL:https://carb-x.org/event/fda-commissioner-unveils-plan-to-combat-antibiotic-resistance-live-webcast/
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20180911T110000
DTEND;TZID=America/New_York:20180911T120000
DTSTAMP:20260404T145934
CREATED:20180829T152008Z
LAST-MODIFIED:20180829T152008Z
UID:1770-1536663600-1536667200@carb-x.org
SUMMARY:Antibacterial drugs: Clinical development for non-developers Webinar
DESCRIPTION:Part 2: Development of antibacterial drugs targeting specific pathogens \nThe overall goal of this series of webinars is to provide\, for the non-clinical developer\, an understanding of the risks of development for various kinds of antibacterial products. Our first webinar was devoted to more traditional approaches (Tiers A and B)\, best suited for more broad-spectrum products\, where the risks are lower. In this webinar\, we will discuss the development of products that target a single species of bacteria where the risks may be higher. While development of therapies for infections caused by a single bacterial species that is identified relatively frequently at a given body site of infection (e.g. Staphylococcus aureus (or even MRSA) in acute bacterial skin and skin structure infections) makes for readily feasible trials\, this is not the case for infrequently occurring infections such as those caused by Pseudomonas aeruginosa or Acinetobacter baumannii. Under these circumstances\, a clinical development program can be very challenging. This webinar will give an overview of the practical challenges associated with developing a therapy for a low frequency event for which treatment must be initiated urgently. The presentation will be followed by an interactive Q&A session. \n 
URL:https://carb-x.org/event/antibacterial-drugs-clinical-development-for-non-developers-webinar/
LOCATION:Webinar
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20180905T080000
DTEND;TZID=America/New_York:20180905T170000
DTSTAMP:20260404T145934
CREATED:20180823T202625Z
LAST-MODIFIED:20180823T202625Z
UID:1763-1536134400-1536166800@carb-x.org
SUMMARY:Vaccines Against Clostridium difficile Infection (CDI): A Roadmap for the Future
DESCRIPTION:There are 453K new C. difficile infections (CDI) every year and 83K recurrent infections\, yet there are no licensed vaccines against this important nosocomial pathogen. The current pipeline of clinical-stage vaccines consists of two toxin-based candidates and one phase 3 candidate\, which is no longer being pursued. Although mathematical studies and computer-simulation models suggest that a CDI vaccine would be a cost-effective approach to protect against disease\, the overall public health impact for a CDI vaccine remains unclear. Moreover\, there are gaps in our understanding of the mucosal immune responses against CDI and how immunity against nontoxin antigens can improve protection. This timely workshop will explore and identify high-priority knowledge gaps in C. difficile pathogenesis and immunology in order to establish a path for future CDI vaccine development\, while considering the public health impact of introducing a licensed vaccine based on anti-toxin immunity.
URL:https://carb-x.org/event/vaccines-against-clostridium-difficile-infection-cdi-a-roadmap-for-the-future/
LOCATION:NIAID Conference Center\, 5601 Fishers Lane\, Rockville\, MD\, United States
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=UTC:20180904T080000
DTEND;TZID=UTC:20180907T170000
DTSTAMP:20260404T145934
CREATED:20180508T182444Z
LAST-MODIFIED:20180709T150858Z
UID:1357-1536048000-1536339600@carb-x.org
SUMMARY:ESCMID/ASM Conference on Drug Development to Meet the Challenge of Antimicrobial Resistance
DESCRIPTION:Drug development for AMR is a rapidly moving field. The stakes are high. A difficult riskbenefit balance must be struck. There are relatively few new classes of antibiotics and each requires highly skilled and experienced investigators to ensure these compounds reach patients. This meeting is the forum where those issues are discussed and debated.
URL:https://carb-x.org/event/escmid-asm-conference-on-drug-development-to-meet-the-challenge-of-antimicrobial-resistance/
LOCATION:Intercontinental Lisbon\, R. Castilho 149\, Lisbon\, 1099-024\, Portugal
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=UTC:20180823T120000
DTEND;TZID=UTC:20180823T130000
DTSTAMP:20260404T145934
CREATED:20180508T182232Z
LAST-MODIFIED:20180810T185121Z
UID:1354-1535025600-1535029200@carb-x.org
SUMMARY:Next Generation Dx Summit: Investment Plenary Panel - Changing Approaches to Sustainable Funding in Diagnostics
DESCRIPTION:Today\, many innovators in the diagnostics industry struggle for funding\, and yet news of large scale acquisitions or large (over $30M) funding rounds pops up regularly. How can innovators better understand the changing dynamics of the funding environment to succeed? How can investors know if they are getting exposed to the potentially best investments? Whether government or private\, what drives the final difficult decisions and how can companies raise their chances of success? This session features leaders from several different channels of funding for innovators\, including the NIH\, other federal programs\, and corporate and traditional venture investors. \nModerator: Bruce Quinn\, MD\, PhD\, Principal\, Bruce Quinn Associates \nPanel includes Tyler Merkeley\, BARDA’s CARB-X Program Manager\, Health Scientist\, Division of CBRN Countermeasures\, BARDA.
URL:https://carb-x.org/event/next-generation-dx-summit-investment-plenary-panel/
LOCATION:Grand Hyatt Washington\, 1000 H St NW\, Washington\, DC\, 20001\, United States
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20180821
DTEND;VALUE=DATE:20180823
DTSTAMP:20260404T145934
CREATED:20180725T185818Z
LAST-MODIFIED:20180810T185233Z
UID:1652-1534809600-1534982399@carb-x.org
SUMMARY:FDA Development of Non-Traditional Therapies for Bacterial Infections Workshop
DESCRIPTION:The Food and Drug Administration is holding a public workshop entitled “Development of Non-Traditional Therapies for Bacterial Infections.” The purpose of the public workshop is to discuss the general development considerations of non-traditional therapies\, including pre-clinical development\, early clinical studies\, and phase 3 clinical trial designs to evaluate safety and efficacy. \nPresentations by Kevin Outterson\, Executive Director of CARB-X\, and John Rex\, Chief Medical Officer of F2G Ltd.
URL:https://carb-x.org/event/fda-development-of-non-traditional-therapies-for-bacterial-infections-workshop/
LOCATION:FDA White Oak Campus – Building 31\, 10903 New Hampshire Ave\, Silver Spring\, MD\, 20993\, United States
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20180809T083000
DTEND;TZID=America/New_York:20180809T123000
DTSTAMP:20260404T145934
CREATED:20180810T193055Z
LAST-MODIFIED:20180810T193147Z
UID:1716-1533803400-1533817800@carb-x.org
SUMMARY:Payment Reform Pathways for Antimicrobial Drugs: Duke-Margolis Center for Health Policy Roundtable Meeting
DESCRIPTION:Facilitating Payment Reform Pathways for Antimicrobial Drugs through FDA and CMS Collaboration \nAs you know\, the rise in antimicrobial resistant infections is a major public health threat. Few treatment options are available and the pipeline of drug candidates is extremely limited. To help address this issue\, Duke-Margolis has been focused on policy initiatives that could encourage development of antimicrobial products through post-market incentives. \nParticipants include Kevin Outterson\, Executive Director of CARB-X
URL:https://carb-x.org/event/payment-reform-pathways-for-antimicrobial-drugs/
LOCATION:Washington\, DC
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20180626T110000
DTEND;TZID=America/New_York:20180626T123000
DTSTAMP:20260404T145934
CREATED:20180621T135932Z
LAST-MODIFIED:20180621T135932Z
UID:1585-1530010800-1530016200@carb-x.org
SUMMARY:GARDP Live Discussion Webinar: PK-PD in support of accelerated programmes for antimicrobial development: how much is enough?
DESCRIPTION:
URL:https://carb-x.org/event/gardp-live-discussion-webinar-pk-pd-in-support-of-accelerated-programmes-for-antimicrobial-development-how-much-is-enough/
LOCATION:Webinar
END:VEVENT
END:VCALENDAR